

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/560,378 Confirmation No.: 9632
Applicant : Toshiyuki HORI
International Filing Date : June 11, 2004
Title : PHARMACEUTICAL COMPOSITIONS FOR PREVENTING
OR TREATING TH1-MEDIATED IMMUNE DISEASES
TC/Art Unit 1614
Examiner: *Unassigned*
Docket No. : 58777.000018
Customer No. : **21967**

Mail Stop Box Sequence
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Substitute Sequence Listing and Statement under 37 C.F.R. §§ 1.821 and 1.825

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.821 and 1.825, Applicant submits herewith a substitute paper copy of "Sequence Listing," totaling four (4) pages. Applicant also submits herewith a substitute computer readable copy of the "Sequence Listing" on a CD-ROM in ASCII format as required by 37 C.F.R. §§ 1.821(e) and 1.825(a).

In accordance with the provisions of 37 C.F.R. § 1.821(f), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the substitute "Sequence Listing" submitted herewith are identical.

In accordance with the provisions of 37 C.F.R. §§ 1.825(a) and 1.825(b), the undersigned hereby states that the content of the computer readable CD-ROM copy of the substitute "Sequence Listing" and the paper copy of the substitute "Sequence Listing" submitted herewith do not constitute new matter.

The amendments included herein are to update the priority information and amend lines <213> and <223> of SEQ ID NOs: 9-16 to comply with U.S. practice. See M.P.E.P. § 2424. The amendments changed line <213> from "Artificial" to "Artificial Sequence". The amendments also changed line <223> from "Artificial sequence" to "Primer".

The undersigned hereby states that the amendments provided herein have support in the specification as filed including the original sequence listing, for example at page 24, ¶ [0035]; and do not constitute new matter.

In accordance with the provisions of 37 C.F.R. § 1.821(a), the undersigned hereby states that the amendment to the paper copy of the "Sequence Listing" is accompanied by a substitute copy of the computer readable form including all previously submitted data with the amendment incorporated therein.

Applicant respectfully requests entry of the substitute "Sequence Listing" submitted herein.

CONCLUSION


It is believed that no additional fees are required with this submission. However, in the event that additional fees are deemed necessary, or in the event of any variance between the amount enclosed and the fees determined by the U.S. Patent and Trademark Office, please charge or credit any such variance to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: 1/22/07

By:


Robert M. Schulman
Registration No. 31,196

Christopher J. Nichols, Ph.D.
Registration No. 55,984

HUNTON & WILLIAMS LLP
Litigation, Intellectual Property & Antitrust
1900 K Street, N.W. Suite 1200
Washington, D.C. 20006
Telephone (202) 955-1500
Fax: (202) 778-2201

RMS/CJN:cdh